Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Receivables (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Receivables data on record, last reported at $6.6 million in Q4 2025.

  • For Q4 2025, Receivables rose 28.59% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $6.6 million, up 28.59%, while the annual FY2025 figure was $6.6 million, 28.59% up from the prior year.
  • Receivables reached $6.6 million in Q4 2025 per TLSI's latest filing, up from $5.0 million in the prior quarter.
  • Across five years, Receivables topped out at $6.6 million in Q4 2025 and bottomed at $1.6 million in Q4 2022.
  • Average Receivables over 4 years is $4.5 million, with a median of $4.9 million recorded in 2024.
  • Peak YoY movement for Receivables: skyrocketed 128.26% in 2023, then increased 1.79% in 2025.
  • A 4-year view of Receivables shows it stood at $1.6 million in 2022, then surged by 128.26% to $3.6 million in 2023, then surged by 43.5% to $5.1 million in 2024, then grew by 28.59% to $6.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $6.6 million in Q4 2025, $5.0 million in Q3 2025, and $5.6 million in Q2 2025.